Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

100 ML Immunoglobulin G, Human 100 MG/ML Injection [Privigen]

Known as: Privigen 10 GM per 100 ML Injection, privigen 10 % in 100 ML Injection, Human Immunoglobulin G 10 g in 100 mL INTRAVENOUS LIQUID [Privigen] 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract This prospective, Phase 3, open-label, study (EudraCT: 2016-001631-12) evaluated pharmacokinetic (PK) characteristics of… Expand
Is this relevant?
2016
2016
PurposeIntravenous IgG (IVIG) treatment wear-off is commonly experienced by patients, who report increased susceptibility to… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2014
2014
BACKGROUND The objective of this study was to evaluate safety and efficacy of Privigen®, a 10% intravenous immunoglobulin (IVIG… Expand
Is this relevant?
2014
2014
PurposeThis retrospective study evaluated the effectiveness and tolerability in clinical practice of an L-proline–stabilized 10… Expand
  • table I
  • table II
  • table III
  • figure 1
  • figure 2
Is this relevant?
2013
2013
This prospective, multicenter, single‐arm, open‐label Phase III study aimed to evaluate the efficacy and safety of Privigen® (10… Expand
Is this relevant?
2012
2012
BackgroundMultiple system atrophy (MSA) is a progressive neurodegenerative disorder of unknown etiology, manifesting as… Expand
  • table 1
  • table 2
  • figure 1
Is this relevant?
2011
2011
  • M. Berger
  • Immunotherapy
  • 2011
  • Corpus ID: 31651592
Liquid IgG preparations are preferred over lyophilized preparations because reconstitution is not required. Formation of dimers… Expand
Is this relevant?
2010
2010
PurposeThe tolerability of L-proline-stabilized Privigen®, a new 10% liquid immunoglobulin for intravenous administration, was… Expand
  • table I
  • figure 1
  • table II
  • table III
  • figure 2
Is this relevant?
2009
2009
The objective of this prospective, open-label, single-arm, Phase III study was to assess the efficacy and safety of Privigen… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PurposeThe present study was designed to evaluate the efficacy and safety of a novel, 10% liquid formulation of intravenous… Expand
  • table I
  • table II
  • figure 1
  • figure 2
  • table III
Is this relevant?